An open-label study assessed the safety, tolerability, and platelet aggregation of varying dosing regimens of cangrelor. [20] Thirty-nine patients (aged 41-77 y) with unstable angina and non-Q ...

Data Synthesis: Cangrelor is a P2Y 12 antagonist under development for treatment of acute coronary syndrome. Cangrelor has been studied as an intravenous infusion in doses of 2 or 4 µg/kg/min.